NCT01778062View on ClinicalTrials.gov

Indacaterol EfectIveness In COPD Patients With Tuberculosis History

PHASE3CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
Interventions
DRUG

Indacaterol

Indacaterol 150µg once daily oral inhalation

DRUG

Control

Placebo once daily oral inhalation

Trial Locations (13)

431-070

Novartis Investigative Site, Anyang-si

410-773

Novartis Investigative Site, Koyang-si

561-712

Novartis Investigative Site, Jeonju

03722

Novartis Investigative Site, Seoul

05505

Novartis Investigative Site, Seoul

110 744

Novartis Investigative Site, Seoul

410-719

Novartis Investigative Site, Koyang

150-713

Novartis Investigative Site, Seoul

405-760

Novartis Investigative Site, Incheon

110-102

Novartis Investigative Site, Seoul

130-872

Novartis Investigative Site, Seoul

143-729

Novartis Investigative Site, Seoul

152-703

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY